Table 1.
Overview of in vivo human trials.
| Study | Type | Score | Patients (n) |
Drug |
Follow up | Outcome |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | Intervention | Type | Dosage | Painmarker |
BPD |
Function |
||||||||||
| VAS | CRP | ESR | Sys | Dias | Grip strength | Morning stiffness | Articular index | |||||||||
| Goto$ [2010] | RCT | RA | 3 | 21 | 23 | Fenofibrate | 200 mg/day | 6 months | 0.67* | 0.1 | –0.03 | 0.06 | –0.07 | - | - | – |
| Bird et al.$ [1983] | RCT | RA | 2 | 31‡ | 25 | Clobuzarit | 100 and 300 mg/day | 24 weeks | ↓* | ↓* | ↓*/↓* | – | – | ↑*/↑* | o/↓* | o/↑* |
| Dixon et al.$ [1983] | RCT | RA | 2 | 60‡ | 30 | Clobuzarit | 100 and 300 mg/day | 24 weeks | – | 0.10/0.85* | – | – | – | 0.60/0.53 | 0.82/0.86* | 0.70/0.75* |
| Reynolds et al.$ [1981] | RCT | RA | 1 | 20 | 20 | Clobuzarit | 50 mg/day | 6 months | – | ↓ | ↓ | – | – | ↑ | ↓ | ↑ |
| McConkey et al.$ [1980] | T | RA | 1 | – | 34 | Clobuzarit | 50–200 mg/day § | 1 year | – | ↓* | ↓* | – | – | – | - | – |
| Forster and McConkey [1986] | T | RA | 0 | - | 3 | Clobuzarit | 200 mg/day | 2 years | – | ↓ | – | – | – | – | – | – |
Outcomes given as effect size (calculated with difference in outcomes for both groups divided by the standard deviation of the outcome).
p < 0.05; –, missing value; ↑, increase, effect size cannot be determined; ↓, reduction, effect size cannot be determined.
Compares with baseline only.
Four groups taken together into patients given clofibrate (100 mg and 300 mg a day) and not given clofibrate.
Started with 50 mg/day and increased in stages to 200 mg/day.
BPD, blood pressure; co, crossover; CRP, C-reactive protein; DAS, disease activity score; Dias, diastolic; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; RCT, randomized controlled trial, SJC, swollen joint count; Sys, systolic; T, trial one group only; TJC, tender joint count; VAS, visual analog score.